A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence
Status:
NOT_YET_RECRUITING
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
The study drug VMB-100 is an mRNA encoding for IGF-1. It is administered by injection into the urethra sphincter, and taken up by the muscle cells. The IGF-1 acts to promote muscle regeneration in the sphincter, which is expected to improve the function of the sphincter and thereby alleviate incontinence (urinary leakage).